CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More
Authors
Keywords
-
Journal
Frontiers in Cell and Developmental Biology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-05-20
DOI
10.3389/fcell.2021.674467
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1
- (2020) Michael D. Crowther et al. NATURE IMMUNOLOGY
- ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
- (2020) S. Depil et al. NATURE REVIEWS DRUG DISCOVERY
- CRISPR-engineered T cells in patients with refractory cancer
- (2020) Edward A. Stadtmauer et al. SCIENCE
- Reshaping Tumor Immune Microenvironment through Acidity-Responsive Nanoparticles Featured with CRISPR/Cas9-Mediated Programmed Death-Ligand 1 Attenuation and Chemotherapeutics-Induced Immunogenic Cell Death
- (2020) Kun Tu et al. ACS Applied Materials & Interfaces
- Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy
- (2020) Xiangrong Song et al. ADVANCED DRUG DELIVERY REVIEWS
- Enhancing the expression and function of an EBV-TCR on engineered T cells by combining Sc-TCR design with CRISPR editing to prevent mispairing
- (2020) Shao-An Xue et al. Cellular & Molecular Immunology
- Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing
- (2020) Hua Alexander Han et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- CRISPR screen in regulatory T cells reveals modulators of Foxp3
- (2020) Jessica T. Cortez et al. NATURE
- Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer
- (2020) You Lu et al. NATURE MEDICINE
- Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth
- (2020) Tsutomu Nakazawa et al. Cells
- CRISPR screen in mechanism and target discovery for cancer immunotherapy
- (2020) Dan Liu et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer
- (2020) Sri Krishna et al. SCIENCE
- Identification of preexisting adaptive immunity to Cas9 proteins in humans
- (2019) Carsten T. Charlesworth et al. NATURE MEDICINE
- Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
- (2019) Brian C. Miller et al. NATURE IMMUNOLOGY
- Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer
- (2019) Wei Zhang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Hacking the Cancer Genome: Profiling Therapeutically Actionable Long Non-coding RNAs Using CRISPR-Cas9 Screening
- (2019) Roberta Esposito et al. CANCER CELL
- Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold
- (2019) David W. Vredevoogd et al. CELL
- Cancer modeling meets human organoid technology
- (2019) David Tuveson et al. SCIENCE
- Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells
- (2019) Matthew B. Dong et al. CELL
- T-Cell Receptor Gene Therapy for Human Papillomavirus–Associated Epithelial Cancers: A First-in-Human, Phase I/II Study
- (2019) Stacey L. Doran et al. JOURNAL OF CLINICAL ONCOLOGY
- In vivo CRISPR screening in CD8 T cells with AAV–Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma
- (2019) Lupeng Ye et al. NATURE BIOTECHNOLOGY
- CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia
- (2019) Lei Xu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion
- (2019) Andrew J. Freeman et al. Cell Reports
- Advances in Detecting and Reducing Off-target Effects Generated by CRISPR-mediated Genome Editing
- (2019) Jin-Jing Li et al. Journal of Genetics and Genomics
- Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
- (2019) Shuang Qin et al. Molecular Cancer
- Simultaneous Deletion of Endogenous TCRαβ for TCR Gene Therapy Creates an Improved and Safe Cellular Therapeutic
- (2019) Laura T. Morton et al. MOLECULAR THERAPY
- Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC
- (2019) Lai Wei et al. Nature Communications
- In vivo epigenetic CRISPR screen identifies Asf1a as an immunotherapeutic target in Kras-mutant lung adenocarcinoma
- (2019) Fei Li et al. Cancer Discovery
- CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma
- (2019) Bryan D. Choi et al. Journal for ImmunoTherapy of Cancer
- Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy
- (2019) Jun Wei et al. NATURE
- Optimizing sgRNA length to improve target specificity and efficiency for the GGTA1 gene using the CRISPR/Cas9 gene editing system
- (2019) Anders W. Matson et al. PLoS One
- CRISPR/Cas9-mediated knockout of DGK improves anti-tumor activities of human T cells
- (2018) In-Young Jung et al. CANCER RESEARCH
- PD-L1+ tumor-associated macrophages and PD-1+ tumor infiltrating lymphocytes predict survival in primary testicular lymphoma
- (2018) Marjukka Pollari et al. HAEMATOLOGICA
- An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
- (2018) Matthew L Cooper et al. LEUKEMIA
- Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
- (2018) Nikolaos Zacharakis et al. NATURE MEDICINE
- Genome-wide CRISPR screen identifies FAM49B as a key regulator of actin dynamics and T cell activation
- (2018) Wanjing Shang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
- (2018) Deng Pan et al. SCIENCE
- CRISPR/Cas9 for cancer research and therapy
- (2018) Tianzuo Zhan et al. SEMINARS IN CANCER BIOLOGY
- Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
- (2018) Stephen J. Pettitt et al. Nature Communications
- PD-L1+ tumor-associated macrophages and PD-1+ tumor infiltrating lymphocytes predict survival in primary testicular lymphoma
- (2018) Marjukka Pollari et al. HAEMATOLOGICA
- Programming CAR-T cells to kill cancer
- (2018) Louai Labanieh et al. Nature Biomedical Engineering
- Reprogramming human T cell function and specificity with non-viral genome targeting
- (2018) Theodore L. Roth et al. NATURE
- Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
- (2018) Marco Ruella et al. NATURE MEDICINE
- Highly efficient genome editing by CRISPR-Cpf1 using CRISPR RNA with a uridinylate-rich 3′-overhang
- (2018) Su Bin Moon et al. Nature Communications
- GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
- (2018) Rosalie M. Sterner et al. BLOOD
- Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function
- (2018) Eric Shifrut et al. CELL
- Cancer diagnosis and immunotherapy in the age of CRISPR
- (2018) Peter J. Cook et al. GENES CHROMOSOMES & CANCER
- Cancer immunoediting and resistance to T cell-based immunotherapy
- (2018) Jake S. O’Donnell et al. Nature Reviews Clinical Oncology
- Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma
- (2018) Xingliang Guo et al. Frontiers in Pharmacology
- CRISPR knock out CTLA-4 enhances the anti-tumor activity of cytotoxic T lymphocytes
- (2017) Long Shi et al. GENE
- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
- (2017) Tomasz M. Beer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
- (2017) Justin Eyquem et al. NATURE
- Identification of essential genes for cancer immunotherapy
- (2017) Shashank J. Patel et al. NATURE
- In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
- (2017) Robert T. Manguso et al. NATURE
- A versatile system for rapid multiplex genome-edited CAR T cell generation
- (2017) Jiangtao Ren et al. Oncotarget
- CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
- (2017) Levi J. Rupp et al. Scientific Reports
- Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9
- (2017) Jiangtao Ren et al. Protein & Cell
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells
- (2017) Yongping Zhang et al. Frontiers of Medicine
- Optimizing T-cell receptor gene therapy for hematologic malignancies
- (2016) Emma C. Morris et al. BLOOD
- A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells
- (2016) Meromit Singer et al. CELL
- Reversing T-cell Dysfunction and Exhaustion in Cancer
- (2016) H. M. Zarour CLINICAL CANCER RESEARCH
- Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
- (2016) Jiangtao Ren et al. CLINICAL CANCER RESEARCH
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
- (2016) Leonid Cherkassky et al. JOURNAL OF CLINICAL INVESTIGATION
- The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non–Small Cell Lung Cancer
- (2016) Roy M. Bremnes et al. Journal of Thoracic Oncology
- Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors
- (2016) Hiroki Torikai et al. MOLECULAR THERAPY
- High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects
- (2016) Benjamin P. Kleinstiver et al. NATURE
- CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes
- (2016) Bastiaan Evers et al. NATURE BIOTECHNOLOGY
- Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR–Cas9 library
- (2016) Shiyou Zhu et al. NATURE BIOTECHNOLOGY
- Driving CAR T-cells forward
- (2016) Hollie J. Jackson et al. Nature Reviews Clinical Oncology
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
- (2016) Aaron Goodman et al. Nature Reviews Clinical Oncology
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia
- (2016) Konstantinos Tzelepis et al. Cell Reports
- Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy
- (2016) D. B. Page et al. Cancer Immunology Research
- CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer
- (2016) Shu Su et al. OncoImmunology
- Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies
- (2015) Laurent Poirot et al. CANCER RESEARCH
- Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells
- (2015) Sanja Stevanović et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma
- (2015) Joal D Beane et al. MOLECULAR THERAPY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rationally engineered Cas9 nucleases with improved specificity
- (2015) I. M. Slaymaker et al. SCIENCE
- Overcoming T cell exhaustion in infection and cancer
- (2015) Kristen E. Pauken et al. TRENDS IN IMMUNOLOGY
- CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
- (2014) Randall J. Platt et al. CELL
- Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma
- (2014) T. Chodon et al. CLINICAL CANCER RESEARCH
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
- (2014) E. Tran et al. SCIENCE
- Immune Modulation in Cancer with Antibodies
- (2013) David B. Page et al. Annual Review of Medicine
- Multiplex Genome Engineering Using CRISPR/Cas Systems
- (2013) L. Cong et al. SCIENCE
- Tolerance and exhaustion: defining mechanisms of T cell dysfunction
- (2013) Andrea Schietinger et al. TRENDS IN IMMUNOLOGY
- A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR
- (2012) H. Torikai et al. BLOOD
- Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma
- (2012) Farhad Azimi et al. JOURNAL OF CLINICAL ONCOLOGY
- CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1
- (2011) J. Fourcade et al. CANCER RESEARCH
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains
- (2011) D H Aggen et al. GENE THERAPY
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
- (2011) Paul F. Robbins et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Tumor Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Analysis of Tumors Resected for TIL
- (2010) Stephanie L. Goff et al. JOURNAL OF IMMUNOTHERAPY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation